ArticleNature chemical biology2018
Structural insights into binding specificity, efficacy and bias of a β
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Nature chemical biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 103 papers.
0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed
8.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 198 citations in OpenAlex.
- A Minimalist Model for Navigating Conformational Landscape Uncovers the Activation Mechanism of βACS physical chemistry Au · 2026Article
- Steric control of signaling bias in the immunometabolic receptor GPR84.Nature communications · 2026Article
- Structural Mechanism of an Efficacy Photoswitch Targeting the βAngewandte Chemie (International ed. in English) · 2026Article
- Molecular mechanisms of native ligand selectivity in catecholamine G protein-coupled receptors.Nature communications · 2026Article
- Molecular basis of CXC chemokine receptor 3 ligand multispecificity.Science advances · 2026Article
- Signaling Bias as a Framework for Therapeutically Relevant Orthosteric Agonists: The βBiochemistry · 2026Article
- Investigating the electrostatics underlying activation of the βBiochimica et biophysica acta. Biomembranes · 2026Article
- Binding pose depth modulates photoswitchable ligands' efficacy at the 5-HTCommunications chemistry · 2026Article
- Article
- Conformational Heterogeneity Underlying Divergent Signaling in Class A G Protein-Coupled Receptors.ACS pharmacology & translational science · 2025Review
- Distinctive patterns of G protein coupling induced by the structurally similar 5-HTMolecular pharmacology · 2025Article
- A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra-Long-Acting βPharmacology research & perspectives · 2025Article
- Recent Developments in the Optical Control of Adrenergic Signaling.Medicinal research reviews · 2025Review
- Molecular basis of ligand binding and receptor activation at the human ANature communications · 2025Article
- Residence time in drug discovery: current insights and future perspectives.Pharmacological reports : PR · 2025Review
- Synthesis and Characterization of Photoswitchable Covalent Ligands for the βAngewandte Chemie (International ed. in English) · 2025Article
- Capillary Zone Electrophoresis-Mass Spectrometry of Intact G Protein-Coupled Receptors Enables Proteoform Profiling.Analytical chemistry · 2025Article
- Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery.Nature reviews. Drug discovery · 2025Review
- Structure and dynamics determine G protein coupling specificity at a class A GPCR.Science advances · 2025Article
- Intracellular GPCR modulators enable precision pharmacology.npj drug discovery · 2025Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
16 authors at 8 institutions in 4 countries.
Matthieu MasureelDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Yaozhong ZouDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Louis-Philippe PicardDepartment of Biochemistry, Institute for Research in Immunology and Cancer, Université de Montreal, Montreal, Québec, Canada.
Emma van der WesthuizenDepartment of Biochemistry, Institute for Research in Immunology and Cancer, Université de Montreal, Montreal, Québec, Canada.ORCID http://orcid.org/0000-0001-9165-8526
Jacob P MahoneyDepartment of Pharmacology, University of Michigan, Ann Arbor, MI, USA.
João P G L M RodriguesDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Thomas J MildorfD. E. Shaw Research, New York, NY, USA.
Ron O DrorD. E. Shaw Research, New York, NY, USA.
David E ShawD. E. Shaw Research, New York, NY, USA.
Michel BouvierDepartment of Biochemistry, Institute for Research in Immunology and Cancer, Université de Montreal, Montreal, Québec, Canada.ORCID http://orcid.org/0000-0003-1128-0100
Els PardonStructural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium.
Jan SteyaertStructural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium.
Roger K SunaharaDepartment of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-1702-8619
William I WeisDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Cheng ZhangDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. chengzh@pitt.edu.ORCID http://orcid.org/0000-0001-9042-4007
Brian K KobilkaDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA. kobilka@stanford.edu.
Stanford University · USD. E. Shaw Research · USInstitute for Research in Immunology and Cancer · CAVrije Universiteit Brussel · BEGenetic Technologies (Australia) · AUUniversity of California San Diego · USUniversity of Michigan · USUniversity of Pittsburgh · US
Funding
INTERDEPARTMENTAL TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007767 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ISOM, LORI L. · 1985 to 2019
$10.2MStructure and dynamics of G protein coupled receptor-G protein complexesR01GM083118 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KOBILKA, BRIAN K, SKINIOTIS, GEORGIOS · 2008 to 2023
$8.3MTHE MECHANISM OF BETA2 ADRENOCEPTOR ACTIVATIONR01NS028471 · NINDS · STANFORD UNIVERSITY · PI KOBILKA, BRIAN K · 1990 to 2021
$6.7MStructure-based discovery of allosteric ligands for G Protein Coupled ReceptorsU19GM106990 · NIGMS · STANFORD UNIVERSITY · PI KOBILKA, BRIAN K · 2013 to 2017
$6.3MEmergent Properties of Complex Systems: From Atoms to Macromolecules; from Humans to SocietiesR35GM122543 · NIGMS · STANFORD UNIVERSITY · PI MICHAEL LEVITT · 2017 to 2026
$5.1MNIGMS NIH HHS R01 GM083118NIGMS NIH HHS R35 GM122543NIGMS NIH HHS T32 GM007767NIGMS NIH HHS U19 GM106990NINDS NIH HHS R01 NS028471
Abstract
Salmeterol is a partial agonist for the β
Indexed as
Adrenergic beta-2 Receptor AgonistsAnimalsAntibodiesAsthmabeta-ArrestinsBinding SitesComputer SimulationCrystallography, X-RayGTP-Binding ProteinsHumansHydrogen BondingLigandsLipidsMutagenesisProtein BindingProtein ConformationAdrenergic beta-2 Receptor AgonistsAntibodiesbeta-ArrestinsGTP-Binding ProteinsLigandsLipidsReceptors, Adrenergic, beta-2Salmeterol Xinafoate
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.